All In Biotech

Investigational drug · Phase 3

AD-218

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mixed Dyslipidemia.

Phase 3

Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "AD-218"

First trial start

2022

Jul 27, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AD-218", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Mixed Dyslipidemia

Approved drugs for the same conditions: Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "AD-218" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Mixed Dyslipidemia

  • ObicetrapibPhase 37 trials

    NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption

  • AD-218APhase 31 trial

    Addpharma Inc. · Mixed Dyslipidemia

  • DW5421APhase 31 trial

    Daewon Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia, Mixed Dyslipidemia

  • DW5421BPhase 31 trial

    Daewon Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia, Mixed Dyslipidemia

  • EDP167Phase 22 trials

    Eddingpharm (Zhuhai) Co., Ltd. · Mixed Dyslipidemia, Homozygous Familial Hypercholesterolemia (HoFH)

  • BW-00112Phase 21 trial

    Shanghai Argo Biopharmaceutical Co., Ltd. · Mixed Dyslipidemia

  • MWX203Phase 21 trial

    Shanghai Minwei Biotechnology Co., Ltd · Mixed Dyslipidemia

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.